Cognitive problems of breast cancer survivors on proton pump inhibitors.
Breast cancer survivors
Cognitive symptoms, concentration, memory
Proton pump inhibitors
Journal
Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
08
2019
accepted:
01
10
2019
pubmed:
15
1
2020
medline:
11
11
2020
entrez:
15
1
2020
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) are used in cancer patients to manage treatment-related gastrointestinal symptoms and to prevent damage to the gastric mucosal lining during treatment. However, PPI use may contribute to cognitive problems. To compare PPI-users and non-users, breast cancer survivors reported cognitive problems in three studies. In Study 1, breast cancer survivors (N = 209; n = 173 non-users, n = 36 PPI-users; stages 0-IIIC) rated their cognitive function on the Kohli scale prior to cancer treatment, as well as one and two years later. In Study 2, women (N = 200; n = 169 non-users, n = 31 PPI-users, stages 0-IIIa, M = 11 months post-treatment) rated their cognitive function on the Kohli scale and BCPT checklist at three visits over a six-month period. In Study 3, participants (N = 142; n = 121 non-users, n = 21 PPI-users; stages I-IIIa, M = 4 years post-treatment) rated their cognitive function on the Kohli scale, BCPT checklist, and Functional Assessment of Cancer Therapy cognitive scale (FACT-cog). In Study 1, PPI-users reported more severe concentration problems (p = 0.039) but not memory problems (p = 0.17) than non-users. In Study 2, PPI-users reported more severe concentration problems (p = 0.022) than non-users, but not memory problems or symptoms on the BCPT (ps = 0.11). Study 3's PPI-users reported more severe memory problems (p = 0.002), poorer overall cognitive function (p = 0.006), lower quality of life related to cognitive problems (p = 0.005), greater perceived cognitive impairment (p = 0.013), and poorer cognitive abilities (p = 0.046), but not more severe concentration problems (p = 0.16), compared to non-users. PPI use may impair breast cancer survivors' memory, concentration, and quality of life.
Identifiants
pubmed: 31933149
doi: 10.1007/s11764-019-00815-4
pii: 10.1007/s11764-019-00815-4
pmc: PMC7183896
mid: NIHMS1549624
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-234Subventions
Organisme : NCI NIH HHS
ID : R01 CA186720
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131029
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA186251
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA126857
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025755
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA172296
Pays : United States
Organisme : NIDCR NIH HHS
ID : T32 DE014320
Pays : United States
Références
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2–3.
doi: 10.1136/bmj.39406.449456.BE
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–7.
doi: 10.1053/j.gastro.2009.03.058
Attwood S, Ell C, Galmiche J, Fiocca R, Hatlebakk J, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74.
doi: 10.1111/apt.13194
Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. Cancer. 1996;78:1447–82.
doi: 10.1002/(SICI)1097-0142(19961001)78:7<1477::AID-CNCR15>3.0.CO;2-X
Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18:463–3.
Wang B-Y, Zhang J, Wang J-L, Sun S, Wang Z-H, Wang L-P, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85.
doi: 10.1186/s13046-015-0194-x
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.
doi: 10.1001/jamaneurol.2015.4791
Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–28.
doi: 10.1007/s00406-014-0554-0
Kuller LH. Do proton pump inhibitors increase the risk of dementia? JAMA Neurol. 2016;73:379–81.
doi: 10.1001/jamaneurol.2015.4931
Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review. J Gastroenterol Hepatol. 2017;32:1426–35.
doi: 10.1111/jgh.13750
Kohli S, Griggs JJ, Roscoe JA, Jean-Pierre P, Bole C, Mustian KM, et al. Self-reported cognitive impairment in patients with cancer. J Oncol Pract. 2007;3:54–9.
Savard J, Ganz PA. Subjective or objective measures of cognitive functioning—What’s more important? JAMA Oncol. 2016;2:1263–4.
doi: 10.1001/jamaoncol.2016.2047
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.
doi: 10.1080/13803390490510905
Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6–15.
doi: 10.1016/j.ejon.2006.02.005
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866.
doi: 10.1200/JCO.2007.10.8639
Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005;97:448–56.
doi: 10.1093/jnci/dji069
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
doi: 10.1177/014662167700100306
Mizyed I, Fass S, Fass R. Gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther. 2009;29:351–8.
doi: 10.1111/j.1365-2036.2008.03883.x
McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009;119:1–8.
doi: 10.1016/j.jad.2009.04.022
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology. 2004;13:61–6.
doi: 10.1002/pon.709
Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment-from bench to bedside. Neuro-Oncol. 2012;14:iv37–44.
doi: 10.1093/neuonc/nos196
Rosano C, Simonsick EM, Harris TB, Kritchevsky SB, Brach J, Visser M, et al. Association between physical and cognitive function in healthy elderly: the health, aging and body composition study. Neuroepidemiology. 2005;24:8–14.
doi: 10.1159/000081043
Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, et al. Age-associated cognitive decline. Br Med Bull. 2009;92:135–52.
doi: 10.1093/bmb/ldp033
Evans DA, Beckett LA, Albert MS, Hebert LE, Scherr PA, Funkenstein HH, et al. Level of education and change in cognitive function in a community population of older persons. Ann Epidemiol. 1993;3:71–7.
doi: 10.1016/1047-2797(93)90012-S
Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, et al. Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32:1040–9.
doi: 10.1200/JCO.2013.51.8860
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.
doi: 10.1200/JCO.1997.15.3.974
Von Ah D, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy—cognitive function instrument. J Pain Symptom Manag. 2015;49:697–706.
Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015;7:79.
doi: 10.1186/s13195-015-0164-8
Park S, Nam JH, Lee H, Chung H, Lee E, Shin J. Beyond uncertainty: negative findings for the association between the use of proton pump inhibitors and risk of dementia. J Gastroenterol Hepatol. 2019.
Hussain S, Singh A, Zameer S, Jamali MC, Baxi H, Rahman SO, et al. No association between proton pump inhibitors use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol. 2019.
Gray SL, Walker RL, Dublin S, Yu O, Aiello Bowles EJ, Anderson ML, et al. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc. 2018;66:247–53.
doi: 10.1111/jgs.15073
Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor–positive female breast cancer. JNCI J Natl Cancer Inst. 2016;108.
Parrilli G, Iaffaioli RV, Martorano M, Cuomo R, Tafuto S, Zampino MG, et al. Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res. 1989;49:3689–91.
pubmed: 2731182
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Can Fam Physician. 2017;63:354–64.
pubmed: 28500192
pmcid: 5429051
Al-Qaisi M, Kahn A, Crowell M, Burdick G, Vela M, Ramirez F. Do recent reports about the adverse effects of proton pump inhibitors change providers’ prescription practice? Dis esophagus. 2018;
Björnsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24:945–54.
doi: 10.1111/j.1365-2036.2006.03084.x
Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56.
doi: 10.1136/gutjnl-2015-310861
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701.
doi: 10.1038/nrn3346
Marlicz W, Koulaouzidis A, Loniewski I, Koulaouzidis G. Letter by Marlicz et al Regarding Article,“Proton Pump Inhibitors Accelerate Endothelial Senescence.”. Circ Res. 2016;119:e31–2.
doi: 10.1161/CIRCRESAHA.116.309157
Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2010;19:573–89.
doi: 10.3233/JAD-2010-1262
Badiola N, Alcalde V, Pujol A, Münter L-M, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8:e58837.
doi: 10.1371/journal.pone.0058837
Fallahzadeh M, Borhani Haghighi A, Namazi M. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010;35:125–6.
doi: 10.1111/j.1365-2710.2009.01100.x